Patents by Inventor Katsushi Kouda
Katsushi Kouda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10030071Abstract: It is an object of the present invention to provide an anti-ITGA6/B4 human antibody, which specifically recognizes ITGA6B4 complex expressed on a cell membrane and inhibits the adhesion of the ITGA6B4 complex to laminin, so as to inhibit adhesion of cancer cells to a bone marrow niche, and which is also capable of remarkably enhancing the effects of an anticancer agent on an anticancer agent resistant strain. The present invention provides an antibody against integrin A6B4, wherein the antibody specifically recognizes a human integrin A6B4 complex and inhibits intercellular adhesion.Type: GrantFiled: September 5, 2014Date of Patent: July 24, 2018Assignees: UNIVERSITY OF MIYAZAKI, FUJITA HEALTH UNIVERSITY, PERSEUS PROTEOMICS INC.Inventors: Kazuhiro Morishita, Kazuko Kaneda, Yoshikazu Kurosawa, Gene Kurosawa, Katsuyuki Mitomo, Katsushi Kouda, Yoshinori Ukai
-
Patent number: 9764041Abstract: It is an object of the present invention to provide a drug conjugate comprising an anti-CDH3 antibody that efficiently kills cancer cells expressing CDH3. According to the present invention, there is provided an immune complex formed by binding an antibody against CDH3 or a fragment thereof having CDH3 binding ability to a chemotherapeutic agent.Type: GrantFiled: April 4, 2012Date of Patent: September 19, 2017Assignee: PERSEUS PROTEOMICS INC.Inventors: Keisuke Ishii, Katsuyuki Mitomo, Katsushi Kouda, Fumiko Nomura, Yoko Kayukawa, Tadashi Matsuura
-
Patent number: 9644028Abstract: The present invention provides an anti-CDH3 humanized antibody having lower immunogenicity, and an anti-CDH3 humanized antibody drug conjugate having the aforementioned anti-CDH3 humanized antibody. The present invention provides a conjugate of an anti-CDH3 humanized antibody and a drug by conjugating a drug having cytotoxicity to an anti-CDH3 humanized antibody having complementarity determining region sequences derived from the heavy chain variable region of an antibody produced by cells having Accession No.Type: GrantFiled: February 14, 2014Date of Patent: May 9, 2017Assignee: PERSEUS PROTEOMICS INC.Inventors: Keisuke Ishii, Katsuyuki Mitomo, Katsushi Kouda, Fumiko Nomura, Yoko Kayukawa, Tadashi Matsuura
-
Publication number: 20160200799Abstract: It is an object of the present invention to provide a novel antibody having a high binding activity and a high neutralizing activity on influenza viruses. The present invention provides an antibody, which neutralizes H1 influenza virus and/or H5 influenza virus, wherein the antibody has a heavy chain variable region having CDRs consisting of a defined heavy chain first complementarity-determining region (VH CDR1), a defined heavy chain second complementarity-determining region (VH CDR2) and a defined heavy chain third complementarity-determining region (VH CDR3), and a light chain variable region having CDRs consisting of a defined light chain second complementarity-determining region (VL CDR2) and a defined light chain third complementarity-determining region (VL CDR3).Type: ApplicationFiled: August 20, 2014Publication date: July 14, 2016Applicants: FUJITA HEALTH UNIVERSITY, THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY, PERSEUS PROTEOMICS INC.Inventors: Yoshikazu KUROSAWA, Nobuko OSHIMA, Yoshinobu OKUNO, Katsuyuki MITOMO, Katsushi KOUDA
-
Publication number: 20160194400Abstract: It is an object of the present invention to provide an anti-ITGA6/B4 human antibody, which specifically recognizes ITGA6B4 complex expressed on a cell membrane and inhibits the adhesion of the ITGA6B4 complex to laminin, so as to inhibit adhesion of cancer cells to a bone marrow niche, and which is also capable of remarkably enhancing the effects of an anticancer agent on an anticancer agent resistant strain. The present invention provides an antibody against integrin A6B4, wherein the antibody specifically recognizes a human integrin A6B4 complex and inhibits intercellular adhesion.Type: ApplicationFiled: September 5, 2014Publication date: July 7, 2016Applicants: UNIVERSITY OF MIYAZAKI, FUJITA HEALTH UNIVERSITY, PERSEUS PROTEOMICS INC.Inventors: Kazuhiro MORISHITA, Kazuko KANEDA, Yoshikazu KUROSAWA, Gene KUROSAWA, Katsuyuki MITOMO, Katsushi KOUDA, Yoshinori UKAI
-
Publication number: 20160152703Abstract: It is an object of the present invention to produce an anti-CDH3 humanized antibody having lower immunogenicity, and to provide an anti-CDH3 humanized antibody drug conjugate comprising the aforementioned anti-CDH3 humanized antibody that more efficiently kills cancer cells expressing CDH3. The present invention provides a conjugate of an anti-CDH3 humanized antibody and a drug by conjugating a drug having cytotoxicity to an anti-CDH3 humanized antibody which comprises complementarity determining region sequences derived from the heavy chain variable region of an antibody produced by cells having Accession No.Type: ApplicationFiled: February 14, 2014Publication date: June 2, 2016Applicant: PERSEUS PROTEOMICS INC.Inventors: Keisuke ISHII, Katsuyuki MITOMO, Katsushi KOUDA, Fumiko NOMURA, Yoko KAYUKAWA, Tadashi MATSUURA
-
Patent number: 9328160Abstract: It is an object of the present invention to provide an anti-cadherin antibody having a high internalization capacity and provide an anti-cadherin antibody-drug conjugate that effectively kills cadherin-expressing cancer cells with the use of such antibody. The present invention provides an anti-cadherin antibody which recognizes a cadherin domain 1 (EC1) of cadherin and exhibits a high internalization capacity.Type: GrantFiled: October 28, 2011Date of Patent: May 3, 2016Assignee: PERSEUS PROTEOMICS INC.Inventors: Keisuke Ishii, Keiko Katsumi, Tadashi Matsuura, Yukio Sudo, Katsuyuki Mitomo, Katsushi Kouda
-
Publication number: 20160058883Abstract: It is an object of the present invention to provide a drug conjugate comprising an anti-CDH3 antibody that efficiently kills cancer cells expressing CDH3. According to the present invention, there is provided an immune complex formed by binding an antibody against CDH3 or a fragment thereof having CDH3 binding ability to a chemotherapeutic agent.Type: ApplicationFiled: April 4, 2012Publication date: March 3, 2016Applicant: PERSEUS PROTEOMICS INC.Inventors: Keisuke ISHII, Katsuyuki MITOMO, Katsushi KOUDA, Fumiko NOMURA, Yoko KAYUKAWA, Tadashi MATSUURA
-
Patent number: 9127061Abstract: It is an object to provide a recombinant antibody that is an anti-CDH3 antibody having cytotoxicity on CDH3-expressing cells, which is anticipated to have fewer side effects than antibodies derived from animals other than humans and to maintain its therapeutic effects for a long period of time. The present invention provides a recombinant antibody which specifically reacts with an epitope existing in the amino acids at positions 108 to 131 or at positions 551 to 654 of the amino acid sequence shown in SEQ ID NO: 38 that is the extracellular region of human CDH3, and has cytotoxicity against CDH3-expressing cells.Type: GrantFiled: June 19, 2012Date of Patent: September 8, 2015Assignee: PERSEUS PROTEOMICS INC.Inventors: Lilin Zhang, Katsuyuki Mitomo, Katsushi Kouda, Yoko Kayukawa
-
Patent number: 9017683Abstract: It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 ?g/mL is 30% or more.Type: GrantFiled: May 3, 2013Date of Patent: April 28, 2015Assignees: The University of Tokyo, Perseus Proteomics Inc.Inventors: Hiroyuki Aburatani, Lilin Zhang, Keisuke Ishii, Katsushi Kouda, Aya Sakamoto, Keiko Katsumi, Hiroshi Onishi, Yoko Kayukawa
-
Publication number: 20140221620Abstract: It is an object to provide a recombinant antibody that is an anti-CDH3 antibody having cytotoxicity on CDH3-expressing cells, which is anticipated to have fewer side effects than antibodies derived from animals other than humans and to maintain its therapeutic effects for a long period of time. The present invention provides a recombinant antibody which specifically reacts with an epitope existing in the amino acids at positions 108 to 131 or at positions 551 to 654 of the amino acid sequence shown in SEQ ID NO: 38 that is the extracellular region of human CDH3, and has cytotoxicity against CDH3-expressing cells.Type: ApplicationFiled: June 19, 2012Publication date: August 7, 2014Applicant: PERSEUS PROTEOMICS INC.Inventors: Lilin Zhang, Katsuyuki Mimoti, Katsushi Kouda, Yoko Kayukawa
-
Publication number: 20130317201Abstract: It is an object of the present invention to provide an anti-cadherin antibody having a high internalization capacity and provide an anti-cadherin antibody-drug conjugate that effectively kills cadherin-expressing cancer cells with the use of such antibody. The present invention provides an anti-cadherin antibody which recognizes a cadherin domain 1 (EC1) of cadherin and exhibits a high internalization capacity.Type: ApplicationFiled: October 28, 2011Publication date: November 28, 2013Applicant: PERSEUS PROTEOMICS INC.Inventors: Keisuke Ishii, Keiko Katsumi, Tadashi Matsuura, Yukio Sudo, Katsuyuki Mitomo, Katsushi Kouda
-
Publication number: 20130245232Abstract: It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 ?g/mL is 30% or more.Type: ApplicationFiled: May 3, 2013Publication date: September 19, 2013Applicants: PERSEUS PROTEOMICS INC., THE UNIVERSITY OF TOKYOInventors: Hiroyuki ABURATANI, Lilin ZHANG, Keisuke ISHII, Katsushi KOUDA, Aya SAKAMOTO, Keiko KATSUMI, Hiroshi ONISHI, Yoko KAYUKAWA
-
Publication number: 20130243771Abstract: It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 ?g/mL is 30% or more.Type: ApplicationFiled: May 3, 2013Publication date: September 19, 2013Applicants: PERSEUS PROTEOMICS INC., THE UNIVERSITY OF TOKYOInventors: Hiroyuki ABURATANI, Lilin ZHANG, Keisuke ISHII, Katsushi KOUDA, Aya SAKAMOTO, Keiko KATSUMI, Hiroshi ONISHI, Yoko KAYUKAWA
-
Patent number: 8455249Abstract: It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 ?g/mL is 30% or more.Type: GrantFiled: April 30, 2010Date of Patent: June 4, 2013Assignees: The University of Tokyo, Perseus Proteomics Inc.Inventors: Hiroyuki Aburatani, Lilin Zhang, Keisuke Ishii, Katsushi Kouda, Aya Sakamoto, Keiko Katsumi, Hiroshi Onishi, Yoko Kayukawa
-
Publication number: 20120136140Abstract: It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 ?g/mL is 30% or more.Type: ApplicationFiled: April 30, 2010Publication date: May 31, 2012Applicants: PERSEUS PROTEOMICS INC., THE UNIVERSITY OF TOKYOInventors: Hiroyuki Aburatani, Lilin Zhang, Keisuke Ishi, Katsushi Kouda, Aya Sakamoto, Keiko Katsumi, Hiroshi Onishi, Yoko Kayukawa